 SDZ MRL novel immunostimulatory monosaccharidic analog improved therapeutic window experimental sepsis SDZ MRL new synthetic monosaccharidic vitro vivo immunopharmacological activities experimental models microbial infections compound protective times immunocompetent mice effective doses SDZ MRL infectious agents route administration cases effective doses times endotoxin Salmonella abortus equi SDZ MRL toxic factor times galactosamine-sensitized mice compound effective inducer tolerance Hence compound transient resistance equal week challenges endotoxin vitro compound devoid intrinsic antimicrobial activity release cytokines monocytes human neutrophils enhanced production reactive oxygen metabolites response soluble stimulus results SDZ MRL useful clinical setting resistance infections patients myelosuppressive chemotherapy irradiation prophylaxis endotoxin shock